Related references
Note: Only part of the references are listed.Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials
M. Monami et al.
DIABETES OBESITY & METABOLISM (2013)
Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials
B. Wang et al.
DIABETES OBESITY & METABOLISM (2013)
Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis
Louise E. Robinson et al.
BMJ OPEN (2013)
Effects of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight: A Meta-Analysis
Matteo Monami et al.
EXPERIMENTAL DIABETES RESEARCH (2012)
Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials
Tina Vilsboll et al.
BMJ-BRITISH MEDICAL JOURNAL (2012)
Efficacy and Safety of Long-Acting Glucagon-Like Peptide-1 Receptor Agonists Compared with Exenatide Twice Daily and Sitagliptin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
Nicole R. Pinelli et al.
ANNALS OF PHARMACOTHERAPY (2011)
Beyond glucose lowering: Glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system
B. Verges et al.
DIABETES & METABOLISM (2011)
Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2-3 liraglutide clinical development studies
Steven P. Marso et al.
DIABETES & VASCULAR DISEASE RESEARCH (2011)
Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control
P. Anagnostis et al.
DIABETES OBESITY & METABOLISM (2011)
Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Events: A Meta-Analysis of Randomized Clinical Trials
Matteo Monami et al.
EXPERIMENTAL DIABETES RESEARCH (2011)
Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials
Remy Boussageon et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
ANNALS OF INTERNAL MEDICINE (2009)
Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials
Matteo Monami et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009)
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
Alan Garber et al.
LANCET (2009)
Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
Arne Astrup et al.
LANCET (2009)
Prevention of cardiovascular disease through glycemic control in type 2 diabetes: A meta-analysis of randomized clinical trials
E. Mannucci et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2009)
Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk
E. Mannucci et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2008)
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study
S Yusuf et al.
LANCET (2004)
Share Paper
